ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers

Kamat, Ashish M.; Hegarty, Paul K.; Gee, Jason; Clark, Peter E.; Svatek, Robert S.; Hegarty, Nicholas J.; Shariat, Shahrokh F.; Xylinas, Évanguelos; Schmitz‐Dräger, Bernd J.; Lotan, Yair; Jenkins, Lawrence C.; Droller, Michael J.; Rhijn, Bas W. van; Karakiewicz, Pierre I.

doi:10.1016/j.eururo.2012.09.057

Cited by 230 publications

(149 citation statements)

References 122 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Cystoscopy is unpleasant, time consuming, and expensive. Therefore, there has been an effort to replace it by a noninvasive diagnostic test, especially in patients with low-risk NMIBC [8,9,10]. However, noninvasive methods of bladder cancer detection still constitute a problem, especially when monitoring patients with a known diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma

Soukup¹,

Kalousová²,

Čapoun³

et al. 2015

Urol Int

View full text Add to dashboard Cite

Objectives: To determine the combination of urinary protein markers for noninvasive detection of primary and recurrent urothelial bladder carcinomas. Methods: Urinary concentrations of 27 biomarkers (NSE, ATT, AFABP, Resistin, Midkine, Clusterin, Uromodulin, ZAG2, HSP27, HSP 60, NCAM1/CD56, Angiogenin, Calreticulin, Chromogranin A, CEACAM1, CXCL1, IL13Ra2, Progranulin, VEGFA, CarbAnhydIX, Annexin-V, TIM4, Galectin1, Cystatin B, Synuclein G, ApoA1 and ApoA2) were assessed by enzyme-linked immunosorbent assay or by electrochemiluminiscence immunoassay. Results: During the primary diagnostics, a group of 70 patients with primary occurrence of bladder cancer and 49 healthy control subjects were compared. For this clinical situation, the most accurate combination proved to be the combination of cytology with markers Midkine and Synuclein G (sensitivity 91.8%, specificity 97.5%). During the monitoring of patients with non-muscle invasive bladder cancer (NMIBC), a group of 44 patients with cancer recurrence was compared with the group of 61 patients with a history of NMIBC without current disease. For this clinical situation, the most accurate combination proved to be the combination of cytology and erythrocytes count in urine sediment with markers Midkine, ZAG2, CEACAM1, and Synuclein G (sensitivity 92.68%, specificity 90.16%). A lower accuracy of the diagnostic panel and the necessity to use more markers in the case of recurrence was connected with a different structure of patients. Conclusions: Multi-marker test can significantly improve the bladder cancer detection both during the primary diagnostics and monitoring of patients with NMIBC. This outcome should result in other, larger studies.

show abstract

Section: Introductionmentioning

confidence: 99%

Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma

Soukup¹,

Kalousová²,

Čapoun³

et al. 2015

Urol Int

View full text Add to dashboard Cite

show abstract

“…Bladder Cancer (BCa) is the second most common malignancy of the genitourinary tract and represents a significant cause of cancer morbidity and mortality [1]. Its incidence and prevalence have been increasing through the last years, although the mortality has decreased.…”

Section: Indroductionmentioning

confidence: 99%

“…Thus, the pathologist receives a specimen without anatomic orientation, has to process many fractions and deal with potentially extensive cautery artefact [1]. The most important information in this analysis is about invasion of the lamina propria or detrusor muscle (muscularis propria).…”

Section: Indroductionmentioning

confidence: 99%

Multicenter Analysis of the Oncological Positivity on Restaging Resection (Re-Turbt) of Urothelial Non-Muscle-Invasive Bladder Cancer

Ferreira¹,

Matheus²,

Neto³

et al. 2017

ARC Journal of Urology

View full text Add to dashboard Cite

Objectives: The main objective was to determine the oncological positivity on restaging TURBT (re-TURBT), in patients submitted to a first complete transurethral resection of bladder tumor (TURBT). Moreover, to verify the most important site of tumor recurrence and changes in the treatment initially proposed. Methods: We retrospectively reviewed the records of patients who underwent a re-TURBT for urothelial nonmuscle-invasive bladder cancer (NMIBC) between

show abstract

“…However, the challenge for clinical and laboratory use is still present when using cfDNA to characterize the mutation status of a tumor. Besides the low copy number of mutant alleles, the median half-life of cfDNA in circulation ranges from 15 minutes to a few hours [26]. Delays in blood processing, blood storage temperature, agitation of the sample, and shipment can cause wild-type cfDNA release from lysed nucleated blood cells and affect allelic frequency [16].…”

Section: Genetic Biomarkersmentioning

confidence: 99%

Some aspects of cancer biomarkers and their clinical application in solid tumors – revisited

Isaac¹,

Elayoubi²,

A³

et al. 2017

J Cancer Res Ther.

View full text Add to dashboard Cite

Cancer biomarkers can be used for a variety of purposes related to screening, prediction, stratification, detection, diagnosis, prognosis, treatment design, and monitoring of a therapeutic response. One of the most important characteristics of a given biomarker includes ease of collection allowing for a non-invasive approach and frequent sampling. Such samples may be obtained from serum or plasma, sputum, bronchoalveolar lavage, saliva, nipple discharge, pleural, or peritoneal effusions. Validation of different biomarkers is considered a mandatory method for useful evaluation. In this review, we highlight the clinical applicability of some cancer biomarkers, as well as future approaches for their development and collection, which may help guide clinicians and researchers. The role of liquid biopsies will also be summarized. Further studies using liquid biopsies are needed to elucidate the significance of various sources of biomarkers suitable for clinical application.

show abstract

ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers

Cited by 230 publications

References 122 publications

Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma

Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma

Multicenter Analysis of the Oncological Positivity on Restaging Resection (Re-Turbt) of Urothelial Non-Muscle-Invasive Bladder Cancer

Some aspects of cancer biomarkers and their clinical application in solid tumors – revisited

Contact Info

Product

Resources

About